NOURNEWS - Senior member of Iran’s National Task Force for Fighting COVID-19 Minou Mohraz said that the coronavirus vaccine, COV-Iran Barekat, which has been developed by Iranian scientists at the Headquarters for Executing the Order of Imam Khomeini (HEIKO), is more efficient than the China-made Sinopharm vaccine.
“COV-Iran Barekat vaccine is more efficient than the Chinese Sinopharm,” said Mohraz, also a senior member of the team to assess the efficiency of the Iran-made vaccine, on Wednesday.
“Based on available assessments, effectiveness of this vaccine in terms of neutralizing antibodies is about 80%; in addition, this vaccine has not shown any serious side effect,” she added.
Mohraz said a limited number COV-Iran Barekat vaccine doses has already been supplied to the market "and by the end of June, another 2 to 3 million doses will be delivered for public vaccination, and then in the next one to two months, several million doses of the vaccine will be produced each month in the main plant".
She had also on Monday said that COV-Iran Barekat vaccine is efficient and has no significant side effects.
“Barekat vaccine has no side effects and one million doses of the vaccine are ready (for injection),” said Mohraz.
She also assured people not to be worried about the shortage of foreign vaccines in Iran, saying that even those who have received the first dose of imported vaccines can use COV-Iran vaccine for their second dose.
In relevant remarks late last month, Head of HEIKO Mohammad Mokhber said that nearly 30 million doses of COV-Iran Barekat vaccine will be produced and delivered to the health ministry.
“One million doses of the vaccine will be produced this month, 3 million doses next month, 10 to 12 million doses in July, and 13 to 15 million doses in August,” Mokhber said, adding that the vaccines would be given to the Health Ministry for vaccination.
He noted that from September, 20 million doses of the vaccine would be produced monthly.
The official pointed out that people's concerns regarding the virus would be resolved within the next 3 to 4 months.
He concluded that all Iranian vaccines had achieved the human testing phase and desirable results, but COV-Iran Barekat has had fewer side effects.
NOURNEWS